ストックスクリーナーアプリを入手
23.62
1.20%
-0.08
前日終値:
$23.70
開ける：
$23.36
24時間の取引高:
34,511
Relative Volume:
0.21
時価総額：
$327.24M
収益：
-
当期純損益:
$-19.48M
株価収益率:
-16.13
EPS:
-1.4641
ネットキャッシュフロー:
$-8.59M
1週間 パフォーマンス:
-2.39%
1か月 パフォーマンス:
+2.61%
6か月 パフォーマンス:
+189.45%
1年 パフォーマンス:
+134.40%
1日の値動き範囲:
$23.00
$23.90
1週間の範囲:
$21.25
$24.90
52週間の値動き範囲:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
名前
Greenwich Lifesciences Inc
セクター
電話
203-434-3290
住所
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
23.62 | 328.35M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
427.29 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
708.32 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.30 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.90 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.99 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-20 | 開始されました | Noble Capital Markets | Outperform |
| 2021-09-01 | 開始されました | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc (GLSI) 最新ニュース
(GLSI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Greenwich LifeSciences delays annual report filing - Investing.com UK
Greenwich LifeSciences delays annual report filing By Investing.com - Investing.com South Africa
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - The Manila Times
Europe trial enrollment jump leaves Greenwich finalizing 10-K figures - Stock Titan
GLSI Stock Price, Quote & Chart | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
Why is GLSI stock rising today? - MSN
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-K filing - MSN
Greenwich LifeSciences (NASDAQ:GLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Greenwich LifeSciences (GLSI) and Actinogen Medical (OtherATGGF) - The Globe and Mail
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
HC Wainwright Has Bearish Estimate for GLSI FY2026 Earnings - MarketBeat
ASCO 2026 to feature Greenwich LifeSciences research poster - Traders Union
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 - ChartMill
GLSI (Greenwich LifeSciences Inc.) reports narrow Q3 2025 EPS beat, shares climb 2.36 percent on positive investor sentiment.Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - ChartMill
H.C. Wainwright Maintains Greenwich LifeSciences(GLSI.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Nasdaq flags Greenwich LifeSciences over delayed 2025 annual report - Stock Titan
(GLSI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
Greenwich LifeSciences shares rise on breast cancer vaccine trial data By Investing.com - Investing.com Canada
Greenwich LifeSciences unveils preliminary FLAMINGO-01 open label data at AACR Meeting - Traders Union
Breast cancer immunotherapy shows 4x immune response in Phase III data - Stock Titan
Is Greenwich LifeSciences (GLSI) stock still attractive (Bullish Sentiment) 2026-04-18Stock Idea Sharing Hub - Xã Thanh Hà
Greenwich LifeSciences (GLSI) Stock Rule Based Trade (Investors Pile In) 2026-04-16Shared Buy Zones - Xã Châu Thành
Greenwich LifeSciences (GLSI) Stock Rights Issue (At Lows) 2026-04-15Viral Trades - Cổng thông tin điện tử tỉnh Lào Cai
Greenwich Lifesciences Provides Clinical Trial and Pipeline Update - National Today
Greenwich LifeSciences reports Q1 cash balance of $10.5 million By Investing.com - Investing.com Australia
Strategic financing update revealed by Greenwich LifeSciences - Traders Union
Greenwich LifeSciences, Inc. Provides Financial Updates and Progress on FLAMINGO-01 Phase III Trial for Breast Cancer Immunotherapy GLSI-100 - Quiver Quantitative
Greenwich LifeSciences reports Q1 cash balance of $10.5 million - Investing.com
Greenwich LifeSciences Provides Update on Financing Strategy - ChartMill
Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Tuesday - MarketBeat
Portfolio Shifts: Can Greenwich LifeSciences Inc expand into new markets2026 Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Greenwich Lifesciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Aug Retail: Will Greenwich LifeSciences Inc benefit from current market trendsTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Will Greenwich LifeSciences Inc benefit from current market trends2026 Market Outlook & Weekly Hot Stock Watchlists - baoquankhu1.vn
(GLSI) Risk Channels and Responsive Allocation - Stock Traders Daily
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 - ADVFN
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential - Sahm
Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim - Seeking Alpha
Greenwich LifeSciences files patent claims for breast cancer therapy By Investing.com - Investing.com South Africa
Greenwich LifeSciences advances new patent claims after FLAMINGO-01 data show statistically significant immune response - Traders Union
Greenwich LifeSciences files patent claims for breast cancer therapy - Investing.com
Greenwich Lifesciences Provides Update On Patent Claims Potentially Doubling Gp2 Market Potential - TradingView
Valuation Update: Can Greenwich LifeSciences Inc expand into new marketsMarket Sentiment Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Greenwich Lifesciences Inc (GLSI) 財務データ
収益
当期純利益
現金流量
EPS
0.83%
2.04%
大文字化:
|
ボリューム (24 時間):